Healthcare Webinars

During the 2024 Military Family Readiness Academy, we will explore the connection between economic security and family well-being and how to address disparities and challenges.  We’ll look beyond achieving and sustaining positive personal and family financial outcomes by exploring how various conditions affect overall economic security. We’ll delve into underlying factors relating to social dynamics, environmental influences, and community characteristics. We’ll give special focus to how these factors relate to health and wellness as a foundation of economic security.  This webinar will help to empower service providers to leverage their knowledge, skills, and available resources to effectively promote health and well-being.Learning Objectives:• Review the various factors, often called the “social drivers of health,” or SDOH, that influence health and well-being.• Promote a mindset that empowers providers to focus on understanding the root causes of health and wellness challenges and to be change agents for positive outcomes.• Recognize that such a mindset requires a holistic or ecological approach to understanding how underlying contextual factors, individual circumstances, institutions, and programs interact with each other.• Examine how various organizations and institutions are fostering efforts to encourage awareness and action to address health disparities and to promote well-being – with a special focus on the U.S. military and the Cooperative Extension system.• Identify various state and federal programs that can contribute to military family health and wellness, with a special focus on TRICARE, VA health benefits, Medicaid, and Medicare.• Consider possible new programs and policy developments relevant to military family health and well-being.A case story is used throughout the course and webinars in the 2024 Military Family Readiness Academy. This case story provides an opportunity to examine resources and services within the Military Family Readiness System. This family’s example asks service providers to consider the skills they need to support family well-being through the lens of economic security. Read the case story here.Presenters: Christopher Plein and Keith G. Tidball

The Inflation Reduction Act and the resulting Medicare Part D price negotiations are shaping up to be the most far reaching of any event impacting pharma manufacturing in recent history.Although the first set of negotiated prices for selected drugs will not take effect until January 1, 2026, the immediate impact has been fast and furious — more than a dozen lawsuits have been filed by pharmaceutical companies, advocacy groups and the US Chamber of Commerce. Industry media is ablaze with discussions on how price negotiations will impact the pricing of non-selected same-class drugs and biosimilars, as well as future drug development in general.With the first-round negotiated prices for selected drugs to be made public on September 1, 2024, companies are preparing themselves for the second round of selections. This timely webinar will provide an update on:To-date information on the legal actions, existing price negotiations, and market reactionsDrugs likely to be selected for the second round and their same-class competitors who will be impactedThe changes and impact of out-of-pocket costs on enrolleesPrice negotiation benchmarking on selected drugs compared to net pricing on competitorsHow manufacturers should prepare for the overall impact to the industryPart D plan utilization managementRegister for this webinar today to understand the profound impact of the Inflation Reduction Act and Medicare Part D price negotiations on the pharmaceutical industry.Speakers: Mark McCoy, RPh, MBA - Director, Client Engagement Pricing Market Access and Reimbursement, ICON; Amith Shetty, PharmD, RPh - Senior Clinical & Market Access Specialist, ICON; Dr. Xin Zhao - Principal, Global Market Access, ICON.Who Should Attend?This webinar will benefit pharmaceutical and biotech professionals in the following areas:Market access/Marketing/Managed markets/Market researchReal world evidenceRegulatory affairsChannel marketingClinical researchCompetitive intelligenceGovernment affairsHealth economics and outcomes researchWhat You Will LearnAttendees will learn about:The ongoing legal challenges initiated by pharmaceutical companies and other stakeholders against the Inflation Reduction Act’s price negotiation provisionsDrugs likely to be targeted in the upcoming rounds of Medicare Part D price negotiationsThe impact of changes to enrollees and drug manufacturers around reductions in patient out-of-pocket costsThe future impact on Part D plan utilization management

Join us for an informative webinar tailored for healthcare providers interested in understanding and recommending serum tears to their patients. Serum tears, derived from a patient’s own blood, offer a natural and personalized treatment option for chronic dry eye and other ocular surface diseases.Our featured presenter, Dr. Matthew Ward, a leading expert in the industry, will guide you through the science behind serum tears, their therapeutic benefits, and the process of preparing and prescribing them.Dr. Ward will cover:• The benefits of serum tears and the compounding process• The cost-effectiveness of serum tears as a treatment option for patients• The safety of serum tears as opposed to traditional eye drops and solutions• And so much more!This session will equip you with the knowledge and tools to confidently recommend serum tears, offering your patients a cutting-edge solution to manage their eye health.Who Should Attend:• Ophthalmologists• Optometrists• Primary care physicians• Healthcare providers involved in ocular care

There has never been a more exciting and promising time in pharmacological research related to obesity drugs. It is now broadly accepted that obesity is not just a lack of willpower but a complex chronic disease with increased morbidity and mortality that can be managed with the right treatment.Over the past decade or so, gut hormone-based drug development targeting obesity and type 2 diabetes indications and combinations of glucagon-like peptide 1 (GLP1) with other gut hormones (glucose-dependent insulinotropic polypeptide (GIP), glucagon and amylin) as dual or triple agonists or other complementary mode of action have increased rapidly.Semaglutide and, most recently, tirzepatide have demonstrated that a two-digit weight loss at one year is achievable and the Phase II data with retatrutide suggest that 100 percent of patients can now achieve the 5 percent weight loss that was targeted in the past. The next stage in obesity research needs to bring affordable and accessible drugs that can lead to selective fat loss, preservation of lean body mass and long-term weight maintenance. As with many other chronic diseases, combination therapies with complementary modes of action will be required to successfully treat patients with obesity.The objective of this webinar is to discuss the potential next steps in pharmacotherapy targeting obesity. The expert speakers will initially focus on the size of the health burden, the history of drug development and the current pipeline in this indication. They will also focus on the current methodologies to assess body composition. They will discuss the potential additional targets, beyond energy intake, to complement and improve the quality of weight loss and its maintenance, as well as present the methodologies that can be used to assess different components of energy expenditure (EE) and explain the concept of metabolic adaptation and the potential physio-pathological mechanisms involved.Moreover, they will discuss the implications of the changes in EE and metabolic adaptation in long-term weight maintenance. Finally, they will focus on brain imaging and how it can help to understand eating behavior and neurocognitive measures in obesity. The webinar will conclude with the current challenges and mitigation strategies for future clinical trials in obesity.Register for this webinar today to understand the latest advancements related to obesity pharmacotherapy.Speakers: Dr. Eric Ravussin, PhD - Boyd Professor, Douglas L. Gordon Chair in Diabetes and Metabolism, Pennington Biomedical Research Center-LSU System, Baton Rouge, Louisiana; Dr. Claudia Filozof - Vice President and Therapeutic Area Head in Obesity, MASH and Liver Indications, Fortrea; Dr. Peter Alfinito, PhD - Executive Director, Operational Strategy & Planning, Fortrea.Who Should Attend?This webinar is designed for drug developers, healthcare professionals, patient advocacy groups and anyone interested in the advancement of obesity drug development.What You Will LearnAttendees will learn about:Understanding obesity’s health burden and the evolution of drug development in obesityMethodologies used to evaluate body composition in the context of obesity researchPotential additional targets beyond energy intake to enhance weight loss quality and maintenanceCurrent challenges in obesity clinical trials and strategies to mitigate these challenges for future research efforts

Join NACDS President & CEO Steve Anderson and national political analyst Charlie Cook in an exciting virtual NACDS RxIMPACT Votes event to learn more about the 2024 elections and what that might mean for the future of pharmacy.Register to attend this virtual event taking place at 1:00pm ET on September 17 – the celebrated National Voter Registration Day inspiring thousands across the nation to register to vote and participate in the 2024 General Election set for November 5, 2024. You won’t want to miss this insightful election forecast and discussion about the 2024 elections and what this might mean in 2025!Can’t make the event? Register for the event and we will share with you a link to the recording!Elected leaders construct not only the laws by which you live, but the laws by which you are able to serve your patients. They introduce bills, pitch resolutions, and offer amendments. The pharmacy community has seen concrete examples over the years of how Governors, state leaders, and members of the U.S. Congress have played a critical role in the future – and fate – of pro-patient and pro-pharmacy policies and whether they are enacted into law. Those elected in November are key to our community’s policy priorities.Register to Attend this Complementary Zoom Event featuring Charlie CookDate: Tuesday, September 17, 2024, Time: 1:00 PM ETNote: Registering for this event will also subscribe attendees to receive NACDS RxIMPACT emails. Contact Hecker@nacds.org with questions.

As more and more clinical trials are conducted internationally, with a higher level of protocol complexity, and with increased competition to get medical products to market faster globally, the need for efficient and streamlined clinical product development is greater than ever.Many clinical teams have experienced delays or bottlenecks in their programs as a result of not getting accurate local-language documentation to sites quickly enough. With companies working to bring innovative therapies to market faster, the effective localization of clinical documentation has never been more critical for success and staying competitive in a constantly evolving landscape.This webinar will bring together industry leaders to explore the critical role of centralized localization in accelerating clinical timelines for global studies. During this webinar, the expert speakers will discuss how centralizing localization of documentation for global studies with the aid of new technologies, including artificial intelligence (AI), can significantly accelerate clinical and product launch timelines.In this webinar, they will also discuss practical ways of leveraging technology automation and AI to streamline the localization process, and how these innovative tools have transformed the way clinical documentation is created and managed, offering unprecedented speed, accuracy and scalability. Through real-world application and case studies, the attendees will discover how leading companies have leveraged these approaches to overcome some of the greatest challenges in clinical product development across multiple languages and regions. One such case study will be a close examination of the clinical programs for vaccines and other treatments for COVID-19, and an analysis of the tactics used to meet unprecedented timelines in those studies that can bring similar time efficiencies to all programs.Register for this webinar today to gain insights into actionable strategies to reduce clinical timelines on a global scale, and to gain great clarity on how a centralized approach to localization can drive efficiency, enhance compliance and ultimately help in clinical product development.Who Should Attend?This webinar will appeal to professionals in the following fields:Clinical operationsRegulatory affairsMedical writingClinical researchPatient recruitmentMedical communicationsWhat You Will LearnAttendees will learn about: How centralizing localization of clinical documentation can drastically reduce timelines for global studiesPractical methods for leveraging technology automation and AI to streamline the localization processInsights from real-world case studies on overcoming challenges in clinical product developmentSpeakers: Kathleen Ruddy - Process & Standards Lead, Global Site & Study Operations, Pfizer; Kristofer Carilli - Senior Manager, Study Startup Management, AbbVie; Quantes Randle - Associate Director, Clinical Operations, Alexion.Moderator: Alexandra Farrell - Regional Director, TransPerfect Life Sciences

Young people living with hepatitis and/or HIV worldwide experience many of the same issues within the hepatitis and HIV responses. To foster meaningful conversations and gather insights from young people living with hepatitis and/or HIV, the World Hepatitis Alliance (WHA) and Y+ Global have partnered to organise a joint webinar. The event will explore the gaps, challenges and solutions for young people living with hepatitis and/or HIV and share stories of young people leading the change in their local communities. Following the webinar, WHA and Y+ Global will take the findings from the discussion to develop new advocacy materials specifically for young people.

Join us for the webinar "Deep Dive in Normal Tension Glaucoma – Update on New Disease Concept and Management" on Saturday, 14 September 2024, at 18:00 GMT+8, Singapore time.This session will delve into comprehensive NTG management, focusing on innovative strategies beyond traditional intraocular pressure (IOP) reduction. Topics will include lowering episcleral venous pressure (EVP), optimizing ocular blood flow (OBF) dynamics, and ensuring 24-hour IOP control. Attendees will explore advanced research, treatment options, and practical approaches to enhance patient outcomes through a multifaceted approach to NTG care.All participants of the webinar will receive a certificate of attendance. Not sure when the webinar takes place in your location? Click here​ to convert the webinar time to your local time.Get Your e-Copy of the Asia Pacific Glaucoma Guidelines (APGG) Version 4!We are excited to announce that attendees of our upcoming webinar will have the exclusive opportunity to receive an e-copy of the latest Asia Pacific Glaucoma Guidelines (APGG) Version 4.How to Qualify:Attend the Webinar: Participation in the webinar is mandatory.Complete the Post-Event Survey: After the event, complete a brief survey to be eligible for the e-copy.Please Note:The e-copy is sponsored by Santen. By requesting this document, you agree to share your details (First Name, Last Name, Affiliation, Email Address, Country) with Santen.The e-copy is for personal use only and requires you to agree to the Personal Use License Agreement before downloading.Availability is subject to certain conditions, including your completion of the post-event survey.Don't miss this chance to access the latest guidelines in glaucoma care!Speakers: Victor Koh, Dexter Leung, Clinical Asso Prof/ Honorary Consultant at HK Sanatorium & Hospital, Hae-Young Lopilly PARK, Professor at The Catholic University of Korea.

On August 23, 2024, Johnson & Johnson sent a notice to 340B covered entities announcing a new method for providing 340B discounts on two of their products, STELARA and XARELTO. This new model requires 340B DSH hospitals to upload claims data to a third-party platform and collect the 340B discount as a rebate instead of accessing 340B prices at the point of sale.This proposed model carries significant financial and operational implications for affected covered entities and is likely to face legal challenges. Our expert-led webinar will address the many questions arising from the 340B community regarding this significant change.Event Details - Date: Thursday, September 12, 2024, Time: 1 PM EST / 10 AM PSTMeet Our Expert Speakers• Nick Gnadt, PharmD, 340B ACE, Director of Pharmacy Professional Services, SpendMend• Greg Wilson, PharmD, 340B ACE, Director of Compliance, SpendMendLearning Objectives:• Review the recent J&J policy notice for accessing 340B discounts for STELARA and XARELTO.• Describe the financial, operational, regulatory, and judicial implications of this practice.• Identify strategies and actions that covered entities may want to consider in response to this new practice.SpendMend webinars are offered at no charge to our prospects, clients, and partners.

Join our upcoming webinar to learn about the FINE-ONE study, which is investigating an innovative treatment aimed at delaying CKD progression in individuals with type 1 diabetes. Shape the future of kidney patient care by learning how you can get involved!Speakers: Paul T. Conway - AAKP Chair of Policy and Global Affairs; Sylvia Rosas, MD, MSCE - Associate Profesor of Medicine, Joslin Diabetes Center, Harvard Medical School.